Latest:
Krista Rubin on Understanding Ipilimumab's Toxicities
Krista Rubin, from Massachusetts General Hospital Cancer Center, on Understanding Ipilimumab's Toxicities.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Kristi McIntyre, MD
Latest:
Dr. McIntyre on Frontline Eribulin in HER2-Negative MBC
Kristi McIntyre, MD, from Texas Oncology, discusses the results of a phase II, multicenter, single-arm study that studies eribulin mesylate as first-line therapy for locally recurrent or metastatic HER2-negative breast cancer.
Kristin J. Richardson, MD
Latest:
Dr. Richardson on the Use of CDK4/6 Inhibitors in HR+/HER2- Breast Cancer
Kristin J. Richardson, MD, hematology/oncology fellow at Rush University Medical Center, discusses the use of CDK4/6 inhibitors in the treatment of patients with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer.
Kristin Rojas, MD
Latest:
Turning the Tide on Opioid Prescribing Practices
As evidence grows that opioids may potentially worsen oncologic outcomes, surgeons and oncology providers must take an active role in addressing the opioid crisis by adopting similar protocols that decrease the quantity of narcotics available for diversion while ensuring safe patient care.
Krithika Subramanian, PhD
Latest:
TILs Show Growing Potential as Novel Immunotherapy
Although checkpoint-blocking antibodies dominate the anticancer immunotherapy field today, researchers are increasingly exploring the potential to leverage growing knowledge about tumor-infiltrating lymphocytes to develop new drugs.
Krystal Knapp, Ben Leach
Latest:
The Year's New Drugs: Integrating Advances of 2011 Into Treatment Plans
The FDA approved more new oncology drugs in 2011 than it has in a single year in more than a decade, thanks in part to priority review and streamlined evaluation procedures. While this is good news for patients, oncology and hematology specialists must tackle the challenges posed by integrating new therapies into treatment plans. Leading specialists give their perspectives on key issues.
Kunle Odunsi, MD, PhD, FRCOG, FACOG
Latest:
Proposed Trial Would Be First Ever for Novel Two-Pronged Immunotherapy Strategy
Roswell Park Cancer Institute is taking
the final steps toward what we believe would be
the first-ever clinical trial combining two novel
and highly promising techniques: adoptive cellular
therapy utilizing re-engineered mature
T cells and re-engineered adult hematopoietic
stem cells.